Welcome to the fourteenth edition of HD Insights, released at the beginning of the 20th International Congress of Parkinson Disease and Movement Disorders in Berlin, Germany. We are grateful to you, our readers, and to our sponsors, for your continued support of our mission to promote, disseminate, and facilitate research in HD.
This edition examines the promise and potential pitfalls of evaluating interventions in patients at-risk for HD. In an interview with Dr. Diana Rosas, we discuss clinical trial designs pioneered by the PRECREST study, which allow at-risk individuals to participate in therapeutic trials without the difficult burden of genetic testing. Dr. Nancy Downing, featured in HD Insights, Vol. 12 as a “Next Generation” HD Scholar, describes her work evaluating lifestyle-based interventions to improve quality of life and potentially delay onset of HD, while Drs. Govinda Poudel and Nellie Georgiou-Karistianis detail their recently published analysis of data from the IMAGE-HD study evaluating imaging markers of neuropsychiatric symptoms in individuals at-risk for HD. Dr. Lise Munsie brings you the highlights of this year’s CHDI meeting, and continues to synthesize the latest HD research in her Research Round-Up feature. As always, we continue to update you on ongoing and recently concluded clinical trials in HD.
This edition of HD Insights also introduces efforts to further connect and encourage HD research collaborations. Dr. Helen Budworth, also featured in HD Insights, Vol. 12 as a “Next Generation” HD Scholar, shares funding opportunities available through the California Institute for Regenerative Medicine. Additionally, through our new Job Opportunities section, we hope to provide another resource for our colleagues in academia and industry to connect to one another and share opportunities. If you have an opportunity you would like featured in HD Insights, please send us an email at email@example.com. As always, we welcome your suggestions, comments, and feedback, and invite you to subscribe electronically by visiting our new website. Thank you for your continued support.
— Ray Dorsey, Editor in Chief
Ray Dorsey’s disclosures: Dr. Dorsey receives grant support from Prana Biotechnology, Teva, Roche, Biomarin, Raptor Pharmaceuticals and the Huntington Study Group.